This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bhattacharya, R. Articles by Mukherjee, P. Search for Related Content PubMed PubMed Citation Articles by Bhattacharya, R. Articles by Mukherjee, P.

Role of Hedgehog Signaling in Ovarian Cancer

Authors' Affiliations: Departments of ¹ Biochemistry and Molecular Biology, ² Experimental Pathology, and ³ Biomedical Engineering, College of Medicine, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Priyabrata Mukherjee or Resham Bhattacharya, Departments of Biochemistry and Molecular Biology and Biomedical Engineering, College of Medicine, Mayo Clinic, Rochester, MN 55905. Phone: 507-284-8563; Fax: 507-284-1767; E-mail: Mukherjee.Priyabrata{at}mayo.edu or bhattacharya.resham{at}mayo.edu.

Purpose: In humans, several distinctive cancers result from mutations that aberrantly activate hedgehog (HH) signal transduction. Here, we investigate the role of HH signaling in ovarian cancer.

Experimental Design: We assessed the expression of different components of hedghehog pathway in primary tumor samples and cell lines. We used specific hedghehog pathway blocker to study the effect on clonal growth and proliferation of ovarian cancer cell both in vitro and in vivo.

Results: We show that the up-regulation of several HH pathway components is a common feature of primary ovarian tumors and cell lines. However, expression of PATCHED1 (PTCH1), a direct transcriptional target of the HH pathway, is down-regulated in ovarian cancer in direct contrast to the expression observed in other adult solid tumors. Cyclopamine, a specific HH pathway inhibitor, inhibits the proliferation and clonal growth of ovarian tumor cells in vitro and arrests ovarian tumor growth in vivo. Expression of BMI-1, a polycomb gene, is down-regulated in ovarian cancer cells following cyclopamine treatment. Overexpression of PTCH1 phenocopied the effects of cyclopamine; it down-regulated BMI-1 and reduced clonal growth in ovarian cancer cell lines. Furthermore, knocking down BMI-1 using small interfering RNA also inhibited the clonal growth of all the ovarian cancer cell lines tested.

Conclusions: In brief, the constitutive low-level expression of PTCH1 contributes to proliferation and clonal growth of ovarian cancer cells by an aberrant HH signal. Because the HH pathway can be inhibited by specific inhibitors, these findings point toward possible new treatments to inhibit ovarian cancer growth.